Richard Valente, MD
Cardiovascular Disease · Waterloo, IANPI 1760464077
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.4% of the total across 167 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 16.3% — the pattern of someone who eats at a lot of different presentations.
Across 167 payments — averaging $18.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$509
- Amgen$261
- Pfizer$252
- Bayer$200
- Abbott$185
- E.r. Squibb & Sons, L.L.C.$179
- plus $2K from 25 others
What the payments were for
- Consulting fees$2006%
- Food & beverage$2,92193%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 35 | $509 |
| Amgen | 16 | $261 |
| Pfizer | 14 | $252 |
| Bayer | 1 | $200 |
| Abbott | 9 | $185 |
| E.r. Squibb & Sons, L.L.C. | 10 | $179 |
| Merck | 8 | $150 |
| Johnson & Johnson | 12 | $125 |
| Inari Medical, Inc. | 4 | $121 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $117 |
| Lexicon Pharmaceuticals, Inc. | 4 | $105 |
| Impulse Dynamics (USA) Inc. | 2 | $95 |
| Boehringer Ingelheim | 6 | $91 |
| AstraZeneca | 6 | $85 |
| Regeneron Healthcare Solutions, Inc. | 6 | $82 |
| Cardiva Medical, Inc. | 3 | $72 |
| Lantheus Medical Imaging, Inc. | 1 | $70 |
| Medtronic | 3 | $69 |
| Boston Scientific | 3 | $52 |
| Phathom Pharmaceuticals, Inc. | 2 | $50 |
| Daiichi Sankyo Inc. | 2 | $40 |
| Novo Nordisk | 2 | $40 |
| Astellas Pharma US Inc | 3 | $39 |
| Actelion Pharmaceuticals US, Inc. | 2 | $33 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $20 |
| Atricure, Inc. | 1 | $19 |
| Philips North America LLC | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Irhythm Technologies, Inc. | 1 | $11 |
| Gilead | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Adempas$200
How this compares
$3,126 in reported general payments places this provider in the 70th percentile of 142 cardiovascular disease providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 347 | $311,745 |
| XareltoRivaroxaban | 143 | $153,892 |
| EntrestoSacubitril/Valsartan | 54 | $60,013 |
| JardianceEmpagliflozin | 55 | $59,943 |
| Repatha SureclickEvolocumab | 82 | $56,110 |
| Repatha SyringeEvolocumab | 61 | $36,609 |
| VascepaIcosapent Ethyl | 39 | $16,566 |
| Praluent PenAlirocumab | 26 | $15,955 |
| Prasugrel Hcl | 105 | $8,350 |
| Metoprolol Succinate | 679 | $6,338 |
| Ezetimibe | 271 | $4,972 |
| Bumetanide | 162 | $3,757 |
| Rosuvastatin Calcium | 347 | $3,161 |
| Flecainide Acetate | 51 | $2,822 |
| ClopidogrelClopidogrel Bisulfate | 324 | $2,719 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $252 | $311,745347 claims |
| Johnson & JohnsonXarelto | $125 | $153,892143 claims |
| NovartisEntresto | $509 | $60,01354 claims |
| Boehringer IngelheimJardiance | $91 | $59,94355 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 142 cardiovascular disease providers in Iowa.
Other cardiovascular disease in Waterloo
- Himanshu TandonWaterloo$7K
- Brian OlshanskyIowa City$219K
- Troy HounshellWest Des Moines$164K
- Enrico MartinWest Des Moines$113K
- Gursukhman Deep SidhuDavenport$60K
- Suzanne FeigofskyWest Des Moines$59K
- Tyler RasmussenCedar Rapids$37K
- Jennifer RobinsonIowa City$37K
- Matthew McMahonCedar Rapids$35K
- Craig StarkDes Moines$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.